Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTAGE family member 13, pseudogene (CTAGE13P), is classified as a pseudogene in the human genome[1][2]. Pseudogenes are non-functional segments of DNA that resemble functional genes but have lost their protein-coding ability or are otherwise non-functional due to mutations or genomic alterations[3]. Most pseudogenes, including CTAGE13P, do not produce functional proteins and are not considered therapeutic or pharmacological targets[1][2][3]. While some pseudogenes can be transcribed and may participate in regulatory processes (e.g., acting as competitive endogenous RNAs or modulating gene expression), there is currently no evidence that CTAGE13P plays any direct or recognized biological, disease, or therapeutic function. It is not associated with any drug interactions, safety concerns, or use as a biomarker. The record likely appears in databases solely because of its sequence similarity to functional CTAGE gene family members; however, it does not encode an active targetable product and should not be considered a molecular target in the pharmaceutical or biomedical sense[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTAGE family member 13, pseudogene (CTAGE13P).